Feasibility of omitting the clinical target volume under PET-CT guidance in unresectable stage III non-small-cell lung cancer: A phase II clinical trial

Dosimetric comparison of nodal clinical target volume for locally advanced non‑small cell lung cancer: Options for geometric expansion vs. lymph node stations

“…To the best of our knowledge, no other study has compared the options for geometric expansion and LN stations, to date. For a somewhat modified comparison, a randomized phase 2 trial was conducted for no geometric expansion without CTV margins vs. LN stations (17). The trial showed that the option without CTV margins had significantly lower DVH parameters for the esophagus, lung, and heart than the option of LN stations (17).…”

“…For a somewhat modified comparison, a randomized phase 2 trial was conducted for no geometric expansion without CTV margins vs. LN stations (17). The trial showed that the option without CTV margins had significantly lower DVH parameters for the esophagus, lung, and heart than the option of LN stations (17). However, this CTV definition without margins was not mentioned in the ESTRO guideline (13).…”

Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer?

“…CTV omission does not compromise failure in the subclinical region. Specifically, for patients with LA-NSCLC, CTV-omitted under PET-CT guidance does not affect efficacy and may reduce severe radiation-associated toxicity 49 . This finding was a single-center phase II trial in which enrolled patients were randomized to receive CTV-omitted under PET-CT guidance (study group) or CTV-delineated (control group) combined with synchronous chemotherapy.…”